APOP - Cellect Biotechnology Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.39
+0.15 (+2.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.24
Open7.23
Bid0.00 x 800
Ask0.00 x 800
Day's Range7.20 - 7.39
52 Week Range6.12 - 13.50
Volume6,470
Avg. Volume12,144
Market Cap46.917M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    Cellect Signed Strategic Agreement with Swiss Biotech Center (SBC)

    TEL AVIV, Israel, July 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that it has entered into a strategic manufacturing and supply agreement with Swiss Biotech Center (SBC) to secure production of FasL protein - Cellect's main active ingredient in ApoGraft™ and the line of Apotainer™.

  • PR Newswire13 days ago

    Cellect Signs Collaboration Agreement With Dresden University denovoMATRIX Team

    Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that it has signed a collaboration and material transfer agreement with the denovoMATRIX group of the Technische Universität Dresden (TU Dresden). TU Dresden and its Center for Regenerative Therapies Dresden (CRTD), is one of the leading centers for stem cell research in Germany.

  • PR Newswire2 months ago

    Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results

    TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire2 months ago

    Former GE Healthcare Executive to Join Cellect as Chief Business Officer

    Andrew Sabatier, formerly the US Sales and Market Development Leader for GE Cell Therapy, will be heading up the commercialization of Cellect Apograft™ technology, as well as new business development. Dr. Shai Yarkoni, Cellect CEO commented: "We are now focusing on building the strongest team possible for the commercialization of our technology. Andrew is one of the most experienced and respected sales executives in this industry with a proven track record of successfully commercializing cell therapy products.

  • PR Newswire3 months ago

    Cellect Announces a Major Milestone for Enabling Stem Cells Production

    Dr. Shai Yarkoni, Cellect CEO commented: "We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. TEL AVIV, Israel, April 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell enabling technology, announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using Cellect's FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products' manufacturing.

  • PR Newswire4 months ago

    Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

    TEL AVIV, Israel , March 19, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a ...

  • PR Newswire5 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    On January 29, 2018, Cellect announced that it had entered into a securities purchase agreement with certain institutional investors for gross proceeds of approximately $4 million. The company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS.

  • PR Newswire5 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    On January 29, 2018, Cellect announced that it had entered into a securities purchase agreement with certain institutional investors for gross proceeds of approximately $4 million. The company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS.

  • CNW Group5 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

  • PR Newswire6 months ago

    Cellect Biotechnology Announces $4 Million Registered Direct Offering

    Cellect Biotechnology Ltd. (APOP), a developer of stem cells selection technology, announced that it has entered into securities purchase agreements with certain institutional investors for gross proceeds of approximately $4 million. In connection with the offering, the Company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS. The warrants have an exercise price of $12.00 per ADS, shall be exercisable immediately following the issuance date and will expire twelve months from the earlier of the effectiveness date of a registration statement registering the shares underlying the warrants and 6 months from the issuance date of the warrants.

  • PR Newswire6 months ago

    Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation

    TEL AVIV, Israel, Jan. 16, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell selection technology, announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect's ongoing Phase I/II study. The study at Hadassah will be conducted under Prof. Polina Stefenski, the Principal Investigator of the site at Hadassah.

  • PR Newswire6 months ago

    Cellect Announces Breakthrough Clinical Results

    First Group of Patients in Clinical Trial With Cellect's ApoGraft Stem Cell Transplant Follow up Results 100% Acceptance and Zero Related Adverse Events Dr. Shai Yarkoni, Cellect CEO commented: "These ...

  • PR Newswire8 months ago

    Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results

    TEL AVIV, Israel , Nov. 22, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire8 months ago

    Cellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in Singapore

    Cellect Biotechnology Ltd. (APOP), a developer of stem cells selection technology, announced today that Company CEO, Dr. Shai Yarkoni, was selected to provide the keynote (Plenary) presentation at the 11th world congress of Regenerative Medicine and Stem Cell technologies (http://www.bitcongress.com/rmsc2017/default.asp ). The event is intended to provide a platform for professionals around the world to exchange state-of-the-art research and development and identify business trends, needs and opportunities in the field of Regenerative Medicine & Stem Cell.

  • PR Newswire9 months ago

    Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies

    TEL AVIV, Israel, Oct. 31, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP),a developer of stem cell selection technology, announced today that Company CEO, Dr. Shai Yarkoni, was chosen to present Cellect technology and recent advancements at the Bio-Europe 2017 conference in Berlin (https://ebdgroup.knect365.com/bioeurope/about-bio-europe) alongside other selected industry leaders including Andrew Yost, VP, Corporate Development, REGENXBIO Inc., Gabriele Proetzel, Director, Regenerative Medicine, Takeda and Sharon Brownlow, Head of Collaborations - Manufacturing Centre, The Cell and Gene Therapy Catapult. The panel will be moderated by the Founder of Alliance of Regenerative Medicine (ARM).

  • SmarterAnalyst9 months ago

    Cellect Biotechnology Ltd. (APOP) Celebrates Major Milestone

    Cellect Biotechnology Ltd. (NASDAQ:APOP) investors are busy throwing a party today following the news that the stem cell developer has achieved a major milestone with the conclusion of a large study on the use ApoGraft™ on stem cells derived from fat tissues. The significance of the findings opens ApoGraft™ to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments. Of special importance are the aesthetic and orthopedic indications where fat-derived stem cells are the main raw material.

  • PR Newswire9 months ago

    Cellect Announces a Major Breakthrough of its ApoGraft™ Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center

    Dr. Shai Yarkoni: "This breakthrough finding is increasing our addressable market by an order of magnitude. TEL AVIV, Israel, Oct 25, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of stem cell selection technology, announced today that it has achieved a major milestone with the conclusion of a large study on the use ApoGraft™ on stem cells derived from fat tissues. The significance of the findings opens ApoGraft™ to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments.

  • PR Newswire9 months ago

    Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer

    Dr. Bakimer-Kleiner has over twenty years of experience as a scientist and executive manager in the biotechnological industrial environment. Ronit has been involved in project planning and management, product development from the bench to production.

  • ACCESSWIRE10 months ago

    Corporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary Endpoints

    Research Desk Line-up: Cellect Biotech Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • ACCESSWIRE10 months ago

    Corporate News Blog - Sage Therapeutics Announces Top-Line Results from Phase-3 STATUS Trial of Brexanolone

    Research Desk Line-up: Cellect Biotech Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • PR Newswire10 months ago

    Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering

    Kasbian Nuriel Chirich, Cellect, Chairman commented "We are well funded to fully execute on our business plan. TEL AVIV, Israel, Sept. 7, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of stem cells selection technology, announced that it has entered into securities purchase agreements with certain accredited investors to receive gross proceeds of $4.3 million. In connection with the offering, the Company will issue 531,136 American Depository Shares (ADSs) at a purchase price reflecting the average share price of six days prior to September 6, 2017 with a 4% discount representing $8.10 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered 12 month, warrant to purchase 50% of the amount raised at an exercise price of $12.07 per ADS.  The closing of the offering is expected to take place on or about September 11, 2017, subject to the satisfaction of customary closing conditions.

  • Cellect Biotechnology (APOP) Soars: Stock Adds 10.2% in Session
    Zacks10 months ago

    Cellect Biotechnology (APOP) Soars: Stock Adds 10.2% in Session

    Cellect Biotechnology Ltd. (APOP) was a big mover last session, as the company saw its shares rise more than 10% on the day.